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1With aging of the general population, an increased inci-dence of conduction disease will result in an increased 
need for permanent pacemaker therapy. According to the 
2015 European Heart Rhythm Association (EHRA) White 
Book, in the 56 member countries of the European Society 
of Cardiology (ESC), the pacemaker implantation rate has 
increased from a mean implantation rate of 614 per million 
inhabitants in 2010 to 641 in 2014, thus growing at a rate of 
about 0.4% to 0.6% per year.1
Much has been learned from clinical studies to identify 
optimal device mode selection and device programming for 
an individual patient to maximize the benefits of cardiac 
implantable electronic device therapy, as well as to minimize 
any potential adverse outcomes caused by ventricular pacing 
(VP). Several clinical studies have reported that chronic right 
ventricular (RV) pacing has detrimental effects on cardiovas-
cular outcomes, including adverse cardiac remodeling, atrial 
fibrillation (AF), congestive heart failure (HF), and mortality. 
The potential mechanism(s) by which RV pacing increases 
the risk for HF and AF are not completely elucidated, but are 
likely caused by both electric and mechanical dyssynchrony, 
disruption of sympathetic/parasympathetic balance that alters 
myocardial activation pattern and contraction sequence, 
thereby modifying myocardial strain resulting in less efficient 
contraction. These changes lead to chamber enlargement, 
functional mitral regurgitation, reduction of parasympathetic/
sympathetic balance in response to reduced ventricular out-
put, and contribute to the development of HF and AF. Notably, 
not all patients paced in the RV experience adverse outcomes; 
these detrimental effects seem to be dependent on a high 
cumulative percentage of RV pacing, generally indicated by 
>40%. Furthermore, the increased risk of HF has been more 
frequently observed in those with pre-existing left ventricu-
lar (LV) systolic dysfunction. A recent review by Gillis2
 has 
covered the optimal pacing mode for RV and biventricular 
devices. It is clear that the abnormal ventricular activation 
sequence generated by spontaneous left bundle branch block 
(LBBB) or by RV pacing itself triggers a remodeling process. 
In the presence of HF and LBBB, simultaneous RV and LV 
pacing or LV pacing by restoring mechanical synchrony has 
profound effects at the genome, proteome, transcriptome, 
metabolome, cellular, and phenome level.3 However, full 
reversal of maladaptive remodeling process at all levels (from 
subcellular to organ level) induced by biventricular pacing is 
strongly related to the percentage of continuous biventricular 
pacing, which shall be as close as to 100% and in any case 
higher than 95% to maximize the effect.4–6
The American Heart Association (AHA)/American 
College of Cardiology (ACC)/Heart Rhythm Society (HRS) 
and ESC/EHRA guidelines recommend the use of pacing 
algorithms to reduce the percentage of VP.7,8 This recommen-
dation is the result of 2 decades of clinical trials that led to 
the deconvolution of the complex electromechanical interac-
tion and effects of pacing on cardiac function and arrhythmias. 
However, the vast majority of clinical trials tested algorithms, 
which reduce VP primarily in patients with sick sinus syn-
drome. Because the most common indication for permanent 
pacing is intermittent or persistent complete atrioventricu-
lar block (AVB)7 (Web Table 3-ESC GDL 2013); the value 
of reducing VP has not been tested adequately in this patient 
group until recently (Table 1).9–22 New studies have evaluated 
the use of an algorithm limiting the frequency of VP in patients 
with advanced or complete AVB (Table 1). The purpose of the 
present review is to report the recent apparently contradictory 
data suggesting more aggressively adopting algorithms that 
reduce the frequency of ventricular pacing in patients with 
AVB—a population for whom we have typically programmed 
continuous and uninterrupted ventricular pacing.
Safety Profile of Algorithmic Reduction in 
Ventricular Pacing in Patients With Intermittent or 
Permanent AVB
Clinical practice guidelines strongly recommend the reduc-
tion of RV pacing for patients with pacemakers implanted for 
sinus node dysfunction (SND).7,8 In patients with intermittent 
bradycardia, pacing may be required only for short periods of 
time. The use of VP minimization algorithms in patients with 
intermittent bradycardia has been rather limited, thus guide-
lines tend to recommend manual programming of AV intervals 
(≤250 ms) or programming AV hysteresis to prevent unneces-
sary RV pacing. In this situation, the benefits of preventing 
bradycardia must be weighed against the detrimental effects 
(Circ Arrhythm Electrophysiol. 2016;9:e004404. DOI: 10.1161/CIRCEP.116.004404.)
© 2016 American Heart Association, Inc.
Circ Arrhythm Electrophysiol is available at http://circep.ahajournals.org DOI: 10.1161/CIRCEP.116.004404
Advances in Arrhythmia and Electrophysiology
Received April 26, 2016; accepted August 2, 2016.
From the Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland (A.A.); and Division of Cardiology, Virginia Commonwealth 
University Medical Center, Richmond (K.A.E.).
Correspondence to Angelo Auricchio, MD, PhD, FESC, Division of Cardiology, Fondazione Cardiocentro Ticino, Via Tesserete 48, CH-6900 Lugano, 
Switzerland. E-mail angelo.auricchio@cardiocentro.org
Reducing Ventricular Pacing Frequency in 
Patients With Atrioventricular Block
Is It Time to Change the Current Pacing Paradigm?
Angelo Auricchio, MD, PhD, FESC; Kenneth A. Ellenbogen, MD
 by guest on September 17, 2016http://circep.ahajournals.org/Downloaded from 
2  Auricchio and Ellenbogen  Reducing Ventricular Pacing in Patients With AV Block 
Table 1. Prospective Randomized Controlled Studies Testing an Algorithm to Reduce Right Ventricular Pacing (AAI/DDD Switching 
Algorithm or AV Delay Hysteresis Algorithm) in Pacemaker Indicated Patients
Study Acronym
Algorithm 
Tested
Pacing 
Indication Study Design Pts (n) Follow-Up (y) Primary End Points
Secondary and Ancillary  
End Points
DANPACE9 AAI/DDD 
modes
SND AAIR vs DDDR 1415 5.4 Death: adjusted HR, 0.94 
(0.77–1.14), P=0.52
Paroxysmal AF: adjusted HR, 
1.24 (1.01–1.52); P=0.042
       Chronic AF: adjusted HR, 1.01 
(0.74–1.39); P=0.93
       Stroke: adjusted HR, 1.11 
(0.70–1.77); P=0.65
       Pacemaker reoperation: 
adjusted HR, 2.00 (1.54–2.61); 
P<0.001
MINERVA10 AAI/DDD 
switching 
algorithm
SND: 83% 3 arms: 
MVP, DDDR, 
DDDRP+MVP
1166 2 Death, cardiovascular 
hospitalization, or permanent 
AF: MVP vs DDDR: adjusted 
HR, 0.89 (0.77–1.03), 
P=0.12
Death: HR, 0.97 (0.71–1.33); 
P=0.84
 MVP AVB: 10%     CV hospitalizations: HR, 0.89 
(0.74–1.08); P=0.23
       Permanent AF: HR, 0.90 
(0.69–1.15); P=0.39
PreFER MVP11,12 AAI/DDD 
switching 
algorithm
SND: 62% MVP vs DDD 605 2.2 CV hospitalization: MVP: 
16.3% vs DDD: 14.5%, 
P=0.72; HR, 1.08 (0.71–1.64), 
P=0.72
Death or CV hospitalization: 
23.9% vs 20.2%; P=0.48
 MVP AVB: 23%     Stroke: 1.5% in MVP vs 2.1% 
in DDD; HR, 0.49 (0.15–1.64); 
P=0.24
       Persistent AF: 15.4% vs 
11.2%; HR, 1.52 (0.95–2.42); 
P=0.08
       Permanent AF: 4.1% vs 3.1%; 
HR, 1.43 (0.57–3.54); P=0.44
       Median VP: 5% vs 86%; 
P<0.0001
ANSWER13,14 AAI/DDD 
switching 
algorithm
SND: 48% Randomized 
(1:1) SafeRTM  
vs DDD
650 3 Median VP at 1 y: 4.8% in 
SafeRTM arm vs 95.4% in DDD 
arm, P<0.0001
Median VP at 3 y: 11.5% in 
SafeRTM arm vs 93.6% in DDD 
arm; P<0.0001
 SafeRTM AVB: 52%    HF hospitalization, AF, or 
cardioversion at 3 y: HR, 0.78 
(0.48–1.25), P=0.30
In AVB pts: median VP at 3 
y: 55.0% in SafeRTM arm vs 
97.9% in DDD arm (P<0.001) 
       Cardiac death or HF 
hospitalization HR 0.49 (0.27–
0.90); P=0.02
       CV hospitalization: HR, 0.70 
(0.49–1.00); P=0.05
       AF onset in patients without 
AA history: HR, 0.77 (0.59–
1.00); P=0.049 40
CAN‐SAVE R15,16 AAI/DDD 
switching 
algorithm
SND: 56% Randomized 
(1:1) SafeRTM  
vs DDD
450 3 Median VP at 1 y: 0% with 
SafeRTM vs 4.0% with DDD, 
P<0.001
Median VP at 3 y: 0% with 
SafeRTM vs 10% with DDD, 
P<0.001
 SafeRTM AVB: 44%    At 3 y no difference between 
groups in AF burden
AF related events: 3.7% with 
SafeRTM vs 8.8% with DDD, 
P=0.04
(Continued )
 by guest on September 17, 2016http://circep.ahajournals.org/Downloaded from 
3  Auricchio and Ellenbogen  Reducing Ventricular Pacing in Patients With AV Block 
EVITA17 VIP OFF vs VIP 
ON (St. Jude)
SND and 
AVB
Randomized 
(1:1)
389 1 Groups VIP OFF and VIP ON in 
patients with compromised 
AV conduction (AVc: AV 
conduction time >325 ms) or 
with intact AV conduction (AVi, 
other patients)
AV conduction over time. At 
baseline 106 patients in the 
AVc had an AV block (12% 
with an episodic AV block III). 
After 12 mo, 113 patients 
were in AVB (P=0.54). In the 
AVi group 5 patients developed 
third-degree AVB (P=0.06)
      Median VP in AVi pts: 1% with 
VIP ON vs 60% with VIP OFF, 
P=0.0001
 
COMPARE18 MVP and 
SAV+
SND: 76% Randomized 
(1:1)
385 1 Median VP:
in SND pts: 0.2% with MVP vs 
1.4% with SAV+, P<0.0001 in 
AVB pts: 11.8% with MVP vs 
98.1% with SAV+, P<0.001
In pts with PR intervals ≥200 
ms, median VP was 1.40% 
with MVP group vs 98.90% 
with SAV+, P=0.004.
  AVB: 23%     Persistent/permanent AF: 
5.8% with MVP vs 4.6% of 
with SAV+
MinVPace19 DDD SND: 92%
AVB: 8%
Randomized 
with triple 
crossover
110 3×2 mo Median VP: 86% in the control 
phase, 2.0% in the MinVP 
phase, 3% in the MinVP+anti-
AF algorithms
Median atrial pacing: 51.5% 
in the control phase, 47.6% in 
the MinVP phase, 81.1% in the 
MinVP+anti-AF algorithms
 MinVP      AF burden: 13.8% in the 
control phase, 14.4% in the 
MinVP phase, 14.7% in the 
MinVP+anti-AF algorithms
 MinVP+anti-
AF algorithms
      
Long MinVP vs DDD SND: 92%
AVB: 8%
Randomized 
(1:1)
66 1.4 Median VP: 5.8% with MinVP 
vs 74% with DDD, P<0.001
Persistent AF: 9% with MinVP 
vs 42% with DDDR, P=0.004
MinVPACE20      AF (device-derived) 12.8% 
with MinVP vs 47.6% with 
DDD, P<0.001
 
IDEAL RVP21 MVP and 
SAV+
SND: 56% Pacemaker 
equipped with 
both algorithms
127 1 mo % of pts with a median 
VP<40%: 66.1% with MVP vs 
54.3% with SAV+
Median AP: 41.1% with MVP 
vs 35.8% with SAV+
  AVB: 46%    % of pts with a median 
VP<10%: 57.5% with MVP vs 
38.6% with SAV+
 
SAVEPACE22 MVP vs DDD SND Randomized 
(1:1)
1065 1.7 Persistent AF: 7.9% in the 
MVP arm vs 12.7% in the 
DDD arm, P=0.004, absolute 
reduction of AF with MVP of 
3.8% at 1 y and 6.9% at 3 y, 
multivariate analysis showed 
a 40% decrease in the relative 
risk of persistent AF with MVP 
compared with DDD
Other predictors of persistent 
AF: age, previous AF, 
antiarrhythmic drug use
       Mortality rate: 4.9% with MVP 
vs 5.4% with DDD
       Hospitalization for HF: 2.8% 
with MVP vs 3.1% with DDD
AA indicates atrial arrhythmia; AAI, single-chamber atrial pacing; AF, atrial fibrillation; AP, atrial pacing; AV, atrioventricular, AVB, atrioventricular block; CV, 
cardiovascular; DDD, dual-chamber pacemaker; HF, heart failure; HR, hazard ratio; MVP, managed ventricular pacing; SAV, search AV; SND, sinus node disease; VIP, 
ventricular intrinsic preference; and VP, ventricular pacing.
Table 1. Continued
Study Acronym
Algorithm 
Tested
Pacing 
Indication Study Design Pts (n) Follow-Up (y) Primary End Points
Secondary and Ancillary  
End Points
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of permanent pacing, particularly pacing-induced HF. In per-
sistent AVB patients, clinical practice guidelines recommend 
the implantation of a dual-chamber pacemaker (DDD) with 
programming of an AV delay in a conventional manner. That 
is because of safety concerns and the lack of data on the use of 
VP management algorithms in permanent AVB at the time of 
clinical practice guidelines publication.
Over the past 2 years, 3 major studies have tested the 
use of an algorithm that reduces VP in a mixed pacemaker 
populations, which also included patients with intermittent 
or permanent AVB (Table 1). Of these studies, 1 study used 
the managed ventricular pacing (MVP) algorithm (Medtronic, 
Minneapolis, MN) and 2 studies tested the SafeR algorithm 
(LivaNova, Clamart, France). The SafeR pacing mode is 
currently the only algorithm that was designed to adapt to 
a patient’s varying AV conduction depending on the sever-
ity of the AV conduction disorder and to combine the ben-
efits of single-chamber atrial pacing (AAI) with the safety of 
DDD pacing (Table 2). Several randomized trials have pre-
viously confirmed effective VP prevention and safety of this 
algorithm. For example in the SafeR study,23 SafeR reduced 
VP over 1 year in selected patients with preserved or mini-
mally impaired AV conduction compared with DDD pacing. 
However, long-term data on the impact of SafeR on the risk of 
developing adverse cardiac events, including syncope, HF or 
AF in patients with intermittent or permanent AVB have been 
lacking until recently. These aspects have been investigated in 
CAN-SAVE R (Canadian Multi-Centre Randomised Study–
Spontaneous Atrioventricular Conduction Preservation)15,16 
and in ANSWER (Evaluation of the SafeR™ Mode in Patients 
With Dual-Chamber Pacemaker Indication).13,14
The CAN-SAVE R study15,16 included 373 patients with 
indications for DDD pacemakers in 10 Canadian centers. 
Patients were randomized 1:1 to SafeRTM or DDD pacing with 
a long AV delay (250 ms); SND was present in 73% (81% 
of whom had no concomitant AVB) and AVB in 41% (66% 
of whom had no concomitant SND). Interestingly, at 1 year 
of follow-up, the median proportion of VP beats was 4.0% 
with DDD versus 0% with SafeR (P<0.001), respectively. 
In the 41% of patients with some degree of AVB at base-
line, median RV pacing rates at 1 and 3 years of follow-up 
remained ≤1% with SafeR compared with 37.3% and 41.8% 
in the DDD group (both P<0.001). At 3 years of follow-up, 
64% of patients in the SafeR group had <1% RV pacing and 
91% had <40% RV pacing. In comparison, corresponding RV 
pacing rates in the DDD group were 34% (P<0.001) and 67% 
(P<0.001). Within the subgroup of patients with intermittent 
AVB, the impact of SafeR remained substantial, with the pro-
portion of RV pacing reduced from 42% to 1%. This marked 
reduction did not compromise patient safety; in contrast, 
80.2% of patients in DDD and 80.6% of patients in SafeR 
mode reported an adverse event, including all-cause death and 
cardiovascular events. Importantly, there were no differences 
between the 2 groups with respect to stroke, HF, or syncope, 
although the number of events was small.
The ANSWER study13,14 enrolled 650 consecutive 
patients with a pacemaker indication at 43 European cen-
ters and randomized them to programming either the SafeR 
algorithm or conventional DDD pacing. Approximately half 
of the population had SND (52%) or AVB (48%); the vast 
majority of patients with AVB had an intermittent AVB. 
Six hundred thirty-two patients were randomized to SafeR 
(n=314) or in DDD (n=318). The ANSWER data showed 
that SafeR can safely reduce VP in a general AVB popula-
tion. In these patients, the SafeR mode showed a significant 
decrease in VP compared with DDD programming (55.0% 
versus 97.9%, P<0.001 at 3 years). The greatest benefit 
was noted in patients with intermittent AVB. Indeed in this 
latter patient group, the SafeR mode showed a significant 
decrease in VP compared with DDD (53.5% versus 98.2%, 
P<0.001 at 3 years). Although patients with permanent 
AVB did not experience any reduction in VP with SafeR, 
the SafeR algorithm appeared to be safe and well tolerated 
in this subgroup. About 40% of patients with either inter-
mittent or permanent AVB randomized to SafeR mode had 
VP <50% over a 3 year time; indicating that, in a sizeable 
proportion of patients with AV conduction disturbance, the 
AV conduction shows significant circadian and monthly 
variation. In other words, AVB is more dynamic than previ-
ously thought. However, in a proportion of patients, inter-
mittent AVB appeared to evolve to permanent AVB. Indeed, 
patients with intermittent AVB treated with SafeR had an 
increase in VP frequency from a mean value of 41.6% at 
1 month to 59.6% at 3 years (Figure 1A, courtesy from M. 
Stockburger). Although these figures were always signifi-
cantly lower than those seen in patients with DDD pacing 
mode, the trend was similar. All together, these data sug-
gest the need for continuous AV conduction assessment 
and management even in patients with intermittent and 
permanent AVB and a more aggressive implementation of 
an algorithm enabling the reduction of VP compared with 
today’s practice of programming a fixed AV interval in this 
subgroup. Importantly, no differences in the occurrence of 
death, syncope, or pacing mode intolerance were observed 
between groups and implant indications.13
 None of the syn-
copal events reported in the ANSWER study was related to 
a recorded complete AVB episode. The event-related anal-
ysis of stored electrograms did not reveal any ventricular 
arrhythmias prompted by SafeR changeovers.14
Possible Consequences of the Use of Algorithm 
Reducing RV Pacing in Patients With Intermittent 
or Permanent AVB
Patients with cardiac implantable electronic device incur an 
increased risk of complications and cost related to pulse gen-
erator replacement.24 Generator lifespan is an important deter-
minant of the cost-effectiveness of pacemaker therapy. The 
current estimated longevity of a modern DDD pulse genera-
tor with a high burden of VP approaches 10 years. Algorithms 
leading to a VP reduction may further and significantly contrib-
ute to device longevity. In the ANSWER study, the significant 
VP reduction achieved by the SafeR pacing mode when com-
pared with standard DDD mode translated into an additional 
calculated gain of about 1 year in device longevity (130.6±23.4 
months and 117.0±20.0 months, respectively).13 This potential 
benefit was similar in SND and intermittent AVB patients. In 
contrast, in patients with permanent AVB, there was no notice-
able effect on device longevity. Stockburger et al13 calculated 
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the effect of the increased device longevity on SafeR versus 
DDD in both intermittent AVB and SND patients on device 
replacement. On average, 28% of women and 23% of men 
would avoid one pulse generator replacement with SafeR pro-
gramming across their lifetime compared with DDD pacing.
Although mode switching algorithms designed to manage 
different types of AVB efficiently reduce RV pacing, the transla-
tion of this reduction into clinical benefit remains controversial 
(Table 1). This controversy stems from the report by Nielsen et 
al9 in the Danish multicenter randomized DANPACE trial (The 
Danish Multicenter Randomized Study on AAI Versus DDD 
Pacing in Sick Sinus Syndrome) of the deleterious impact of 
long PR intervals in patients with SND.25 The authors showed 
that patients with SND and prolonged PR interval should be 
preferably treated with DDDR pacing with an individually 
programmed moderately prolonged AV delay. These results 
are in line with previous findings in a large community-based 
cohort study, where a PR interval >200 ms was associated 
with a 2-fold increased risk of AF onset when compared with 
a shorter PR interval.26 The issue of PR prolongation is prob-
ably even more pronounced in patients with AVB. Although 
previous small noncontrolled studies with short follow-up 
reported effective VP prevention in patients with AVB through 
the MVP AAI-DDD changeover algorithm,27 the application 
of the MVP mode in patients with AVB has been questioned 
because of the possibility of excessively long AV delays.28–34 
These concerns were amplified in a trial of MVP in patients 
receiving a pulse generator or an ICD. The MVP algorithm 
Table 2.  Description of the 5 Algorithms Designed to Reduce Unnecessary VP
Managed Ventricular Pacing (MVP Medtronic, Minneapolis, MN)
  Atrial-based pacing in AAI(R) with switch to DDD(R) if AV block is detected, defined as 2/4 absent ventricular events. The algorithm checks for AV conduction at 
regular intervals and if present, it will switch back to AAI(R)
  MVP remains in AAI if first AV block degree is detected; the user manual recommends programming to DDD
Search AV+ (SAV+, Medtronic, Minneapolis, MN)
  The pacemaker searches for the patient’s intrinsic AV conduction time and adjusts the SAV and PAV intervals either longer or shorter to promote intrinsic 
activation of the ventricles. The pacemaker assesses the 16 most recent AV conduction sequences and adapts the operating SAV and PAV intervals to the 
observed conduction time (either lengthens the operating SAV and PAV intervals by 62 ms for the next 16 pacing cycles to promote intrinsic conduction 
or shortens the operating SAV and PAV intervals by 8 ms for the next 16 pacing cycles). The maximum amount of time by which the SAV and PAV can be 
lengthened is limited by the Search AV+ Maximum Increase to AV parameter
Reverse Mode Switch (RYTHMIQ, Boston Scientific, St. Paul, MN)
  Atrial-based pacing in AAI(R) with VVI backup (LRL minus 15/min), the 2 modes operate independently from one another. If complete AVB occurs, ventricular 
pacing will be delivered at backup VVI rate, asynchronous to the AAI rate. If 3 slow ventricular beats are detected in a window of 11 beats, AV conduction is 
considered blocked and switch to DDD(R) takes place. The algorithm will switch back to AAI if intact AV conduction is recuperated
  AAI to DDD switch when the VV intervals are longer than A-A+150 ms for several beats (no AV interval criterion). The pacemaker will not switch if progressive 
PR prolongation occurs and the VV interval stays shorter than AA+150 ms
SafeRTM mode (LivaNova, Clamart, France)
  Atrial-based pacing in AAI (R). Switch to DDD(R) in response to any of the following:
     •   AAI to DDD switch on 6 consecutive PR intervals longer than the programmed long PR limit (AVB I criteria). The allowed duration of PR varies with the heart 
rate. In addition, the maximum allowed duration of PR intervals is programmable (physicians’ choice)
     •   3/12 non conducted atrial events (AVB II criteria)
     •   2 consecutive non conducted atrial event (AVB III criteria), ventricular pauses of 2–4 s (programmable)
Ventricular Intrinsic Preference (VIP, St. Jude Medical, Sylmar, CA)
  Intrinsic AV conduction is assessed by increasing AV delay at regular intervals (programmable AV extension of ≤200 ms; maximum AV delay 350 ms). If present, 
the longer AV delay will be maintained until a programmable number of cycles of absent ventricular sensed events (ie, continuous need for ventricular pacing), 
thus deactivating the algorithm.
AV hysteresis (Biotronik, Berlin, Germany)
  Similar to Ventricular Intrinsic Preference (St. Jude)
VP suppression (Biotronik, Berlin, Germany)
  In ADI(R) mode, intrinsic conduction is monitored within a 450 ms interval after each atrial event. A cycle without intrinsic ventricular conduction triggers a 
further 8-cycle evaluation period. If any of the following criteria are met, the device reverts to DDD(R):
     •   2 consecutive cycles without intrinsic ventricular conduction
     •   a programmable number (1–8) out of 8 cycles without intrinsic conduction
     •   no VS event for 2 or more seconds
If the long PR interval is shorter than 450 ms, the pacemaker will not switch to DDD
AAI indicates single-chamber atrial pacing; AV, atrioventricular, AVB, atrioventricular block; DDD, dual-chamber pacemaker; MVP, managed ventricular pacing; SAV, 
search AV; and VP, ventricular pacing.
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was associated with more HF and worse outcomes in patients 
with longer PR intervals.12,35,36 The adverse hemodynamic 
effects of long PR intervals, through prolonged intrinsic AV 
conduction, comprise shortening and impairment of LV filling 
and increased left atrial pressure. In some patients, symptoms 
resembling pacemaker syndrome are provoked by the unfa-
vorable prolongation of the AV electromechanical sequence. 
Hence, VP prevention in the case of marked first-degree AVB 
may unintentionally impair hemodynamics, despite preserving 
ventricular synchrony, a situation which may be amplified in 
patients with decreased LV function.
Do All Ventricular Pacing Minimization Algorithms 
Behave the Same in Patients With AVB?
The algorithms available for minimizing RV pacing include 
programming long AV delays or dynamic extension of AV 
delays (hysteresis), or the use of specific algorithms for RV 
pacing minimization switching from AAI to DDD pacing in 
the presence of AVB. AV delay extension algorithms have been 
designed for occasional AVB or first-degree AVB in patients 
with SND, but not for second- or third-degree AVB manage-
ment; therefore, they are not further discussed in this article.
The algorithms designed to minimize VP operate by pro-
longing the AV interval with hysteresis or by switching between 
DDD and AAI modes are summarized in Table 2. The opera-
tive features differ between manufacturers, but all carry the risk 
of AV decoupling (defined as >40% increase of AV intervals 
over 300 ms) even when the baseline PR interval is normal, thus 
leading to worsened clinical outcomes.35 This adverse effect is 
addressed differently (or not addressed at all) according to the 
specificities of each manufacturer’s algorithm (Table 2).
MVP does not switch from AAI to DDD mode as long as 
a ventricular event is detected between 2 normal atrial events 
(paced or sense); consequently, it will not pace the ventri-
cles in case of markedly prolonged PR intervals, which can 
adversely affect cardiovascular hemodynamics, reducing atrial 
contribution to ventricular filling and favoring diastolic mitral 
regurgitation.26 In addition, prolonged PR intervals lead to AV 
decoupling which may trigger increased sympathetic activation 
and, in some patients, autonomic reflexes leading to symptoms 
of pacemaker syndrome. Lim37 has recently indicated that this 
algorithm should be confined to patients in sinus rhythm with 
SND, narrow QRS (<120 ms), and no significant AV conduc-
tion disease, and that patients with second- or third-degree AVB 
should not be prescribed MVP. The recently published pro-
spective, randomized PREFER MVP study (Prefer MVP for 
Elective Replacement) has indicated that the lack of adequate 
PR management can be detrimental to patients11,12: 605 patients 
referred for generator replacement of a pacemaker or ICD 
were enrolled if they had a history of >40% VP. Patients were 
allocated to receive either standard DDD or MVP pacing.11 A 
secondary analysis of the study12 showed that history of atrial 
arrhythmias and VP% ≥10%, estimated in the first 3 months, 
were independent predictors for persistent atrial arrhythmias 
observed in 71 patients (11.7%) after 2 years of follow-up, and 
that MVP was associated with an increased risk of persistent 
atrial arrhythmias (hazard ratio [HR], 3.41; 95% confidence 
interval, 1.10–10.6; P=0.024) in the subgroup of patients with 
baseline long PR interval (PR>230 ms). This is consistent with 
the results from the earlier study of Sweeney et al.36
The SafeR algorithm was designed to manage PR prolon-
gation in patients with AVB as long as in patients with other 
atrioventricular conduction disorders (Figure 2). In particu-
lar, the algorithm switches from AAI to DDD when 6 long 
PR intervals (programmable) are detected (Table 2). As PR 
evolves according to patients’ activity, the AVB I degree cri-
terion can be programmed either to rest+exercise (the device 
will switch to DDD during rest and exercise phases) or to 
exercise only (the device will switch to DDD during exercise 
phase only). Stockburger et al38 reported the validation of the 
SafeR algorithm for all types of AVB and its safety profile in 
both SND and AVB populations.13
The management of long PR seems particularly relevant as 
recent analyses on the ANSWER database showed that 25% of 
Figure 1. A, Ventricular pacing frequency (mean, 95% confidence intervals [CIs]) in patients with intermittent atrioventricular (AV) block 
treated with SafeR in the evaluation of the SafeRTM mode in patients with dual-chamber pacemaker indication (ANSWER) study; increase 
from a mean value of 41.6% at 1 mo to 59.6% at 3 y, mean difference intrapatient of 20%. B, Freedom from paroxysmal atrial fibrillation 
in complete AV block patients without history of atrial fibrillation at baseline included in the ANSWER study. DDD indicates dual-chamber 
pacemaker; and HR, hazard ratio.
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patients with SND and 48% of patients with AVB had a long 
PR at baseline (>230 ms), responsible for a high proportion of 
AVB I degree switches, and that patients with long PR (≥230 
ms) were 1.68 more likely to develop persistent AF (HR, 1.68; 
95% confidence interval, 1.06–2.65; P=0.027).39 In addition, 
SafeR was associated with a 35% risk reduction in AF onset 
over 3 years in AVB patients without history of atrial arrhyth-
mias (HR, 0.65; 95% confidence interval, 0.43–0.98; P=0.038; 
Figure 1B).40 This result remains in agreement with previously 
published data.41 Other VP algorithms are briefly summarized 
in Table 2.
BIOPACE, BLOCK HF, and MADIT-CRT 
Implication for Reduced Ventricular Pacing Mode
The recent results of both ANSWER and the CAN-SAVE R 
study should be further assessed within the context of recent 
studies on the management of patients possibly requiring a 
high VP burden.
The BIOPACE study (Biventricular Pacing for 
Atrioventricular Block to Prevent Cardiac Desynchronization) 
failed to meet its primary objective (mortality and HF hos-
pitalization) to determine whether synchronous BiV pacing 
confers a clinical benefit in patients with conventional indica-
tions for permanent VP, regardless of spontaneous QRS dura-
tion and morphology or LV size and function, by preventing 
iatrogenic ventricular desynchronization because of unilateral 
RV pacing.42 In the BIOPACE study, the mean LV ejection 
fraction was 55%±12% and the trial included only a low pro-
portion of patients with complete AVB or PR interval above 
230 ms. The mean follow-up was 67 months. The BLOCK-HF 
study (Biventricular Versus Right Ventricular Pacing in Heart 
Failure Patients With Atrioventricular Block) met its primary 
end point and showed that BiV reduces the risk of all-cause 
mortality, HF-related urgent care visits, or an increase ≥ 15% 
LV end systolic volume index for patients with AVB and sys-
tolic dysfunction.43 Notably, the positive result in BLOCK-HF 
was almost solely driven by changes in LV end systolic vol-
ume and not clinical end points. Pacemaker patients included 
in BLOCK-HF had a mean LV ejection fraction of 44±6.5% 
and an LV ejection fraction lower than that reported in the 
BIOPACE study; moreover, the mean follow-up time was only 
about half of the BIOPACE study. Another important peculiar-
ity of BLOCK-HF study was the device programming in the 
group randomized to conventional DDD pacemaker; in these 
latter patients, the AV interval was programmed to result in 
continuous RV pacing, which may have provoked significant 
LV dyssynchrony.
A recent subanalysis of MADIT-CRT study (Multicenter 
Automatic Defibrillator Implantation With Cardiac 
Resynchronization Therapy) evaluating the importance of 
long PR interval (>230 ms) in patients with non-LBBB, show-
ing that only those HF patients with a long PR interval and 
non-LBBB QRS derive a significant clinical benefit from the 
implantation of CRT-D versus ICD-only.44 In contrast, patients 
with non-LBBB implanted with CRT-D with a normal PR 
interval have an increased risk of all-cause mortality compared 
with ICD only therapy, suggesting a significant bidirectional 
interaction between baseline PR interval and clinical benefit 
Figure 2. Distribution of single-chamber atrial pacing to dual-chamber pacemaker switches in sinus node dysfunction (top left), and atrio-
ventricular block (AVB) patients of first degree (top right), second degree (bottom left), and complete block (bottom right) of the evalu-
ation of the SafeRmode in patients with dual-chamber pacemaker indication (ANSWER) study included in the SafeR arm. SND indicates 
sinus node dysfunction.
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from CRT-D in the non-LBBB population. Furthermore, this 
MADIT-CRT subanalysis confirmed that the PR interval is a 
powerful prognostic marker of cardiac events in patients with 
non-LBBB, mild HF, and a wide QRS. Thus, taken together 
the results of BIOPACE, BLOCK-HF, ANSWER, CanSaveR, 
and MADIT-CRT suggest the possibility that, in patients with 
advanced AVB, the use of an algorithm which significantly 
reduces VP shall be preferred, whereas in those patients with 
moderately depressed LV ejection fraction and markedly pro-
longed PR, a biventricular device shall be preferred to a con-
ventional DDD pacemaker (Figure 3).
Conclusions
We should reconsider the opportunity for VP reduction for patients 
with AVB in the light of these recent studies. Unfortunately, not all 
algorithms are the same, some do not adequately manage long PR 
intervals and clinicians would benefit from further improvements 
of algorithms. Recently published studies highlight the fact that 
reduction of %VP can be achieved safely even in patients with 
AVB while managing a long PR interval. Such an option might be 
preferred over implanting a more complex CRT-P system.
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